- In November 2024, Avalon GloboCare launched the "BrAce for Impact" affiliate marketing program for its KetoAir breathalyzer device. This initiative enables affiliates—including health coaches, influencers, and content creators—to promote KetoAir™ by offering discount codes and earning commissions on each sale. The program was developed in response to demand from attendees at health conferences earlier in the year
- In May 2024, Cannabix Technologies launched the Breath Logix Workplace Series, a compact, wall-mounted alcohol breath detection device designed for workplace safety. The device offers automated sobriety checks, user identification via photo capture, and real-time alerts for positive alcohol results. It features a low-maintenance pre-calibrated cartridge system and supports various workplace testing scenarios. The company is also preparing to deliver units for evaluation and potential distribution in South Africa
- In September 2024, Owlstone Medical entered into a five-year research collaboration with the U.S. Food and Drug Administration's Center for Devices and Radiological Health – Office of Science and Engineering Laboratories. This partnership aims to develop validated analytical methods for the confident identification of volatile organic compounds in exhaled breath, enhancing the detection of disease biomarkers
- In August 2024, Trudell Medical Limited announced its expansion into respiratory diagnostics through an agreement to acquire the RDx business unit of Vyaire Medical. RDx specializes in manufacturing respiratory diagnostic products, and this acquisition aims to enhance Trudell's capabilities in providing comprehensive respiratory care solutions
- In April 2023, GSK announced its agreement to acquire BELLUS Health, a Canada-based biopharmaceutical company specializing in treatments for refractory chronic cough (RCC). The acquisition, valued at approximately $2 billion, provides GSK with access to camlipixant, a highly selective P2X3 antagonist currently in Phase III development
